Atkins Marvin D, Kwolek Christopher J, LaMuraglia Glenn M, Brewster David C, Chung Thomas K, Cambria Richard P
Division of Vascular and Endovascular Surgery of the General Surgical Services, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
J Vasc Surg. 2007 Jun;45(6):1162-71. doi: 10.1016/j.jvs.2007.01.067. Epub 2007 Apr 30.
Endovascular therapy (percutaneous transluminal angioplasty [PTA] with stenting) has been increasingly applied in patients with chronic mesenteric ischemia (CMI) to avoid morbidities associated with open repair (OR). The purpose of this study was to compare outcomes of PTA/Stent vs OR in patients with symptomatic CMI.
During the interval of January 1991 to December 2005, 80 consecutive patients presenting with symptomatic CMI underwent elective revascularization. Patients with acute mesenteric ischemia or those with mesenteric revascularization performed as part of complex aneurysm repair were excluded. PTA/Stent (with stenting in 87%) was the initial procedure in 31 patients (42 vessels). OR was performed in 49 patients (88 vessels) and consisted of bypass grafting in 31 (63%), transaortic endarterectomy in 7 (14%), patch angioplasty in 4 (8%), or combined in 7 (15%). Mean follow-up was 15 months in the PTA/Stent group and 42 months in the OR cohort. Study end points included perioperative morbidity, mortality, late survival (Kaplan-Meier), and symptomatic and radiographic recurrence.
Baseline comorbidities, with the exception of heart disease (P=.025) and serum albumin<3.5 g/dL (P=.025), were similar between PTA/Stent and OR patients. The PTA/Stent group had fewer vessels revascularized (1.5 vs 1.8 vessels, P=.001). Hospital length of stay was less for the PTA/Stent group (5.6 vs 16.7 days, P=.001). No difference was noted in in-hospital major morbidity (4/31 vs 2/49, P=.23) or mortality (1/31 vs 1/49, P=.74). Actuarial survival at 2 years was similar between the groups (88% PTA/Stent vs 74% OR, P=.28). There was no difference in the incidence of symptomatic (7/31 [23%] vs 11/49 [22%], P=.98) or radiographic recurrence (10/31 [32%] vs 18/49 [37%], P=.40) between the two groups. Radiographic primary patency (58% vs 90%, P=.001) and primary assisted patency (65% vs 96%, P<.001) at 1 year were lower in the PTA/Stent group compared with OR. Five (16%) of 31 PTA/Stent patients compared with 11 (22%) of 49 OR patients required a second intervention on at least one index vessel at any time (P=.49).
Symptomatic recurrence requiring reintervention is common (overall 16/80 [20%]) after open and endovascular treatment for CMI. PTA/Stent was associated with decreased primary patency, primary assisted patency, and the need for earlier reintervention. In-hospital mortality or major morbidity were similar in patients undergoing PTA/Stent and OR. These findings suggest that OR and PTA/Stent should be applied selectively in CMI patients in accordance with individual patient anatomic and comorbidity considerations.
血管内治疗(经皮腔内血管成形术[PTA]并置入支架)已越来越多地应用于慢性肠系膜缺血(CMI)患者,以避免与开放修复(OR)相关的并发症。本研究的目的是比较有症状CMI患者接受PTA/支架治疗与OR治疗的结果。
在1991年1月至2005年12月期间,80例有症状CMI的连续患者接受了选择性血运重建。排除急性肠系膜缺血患者或作为复杂动脉瘤修复一部分进行肠系膜血运重建的患者。PTA/支架治疗(87%置入支架)是31例患者(42条血管)的初始治疗方法。49例患者(88条血管)接受了OR治疗,其中31例(63%)行旁路移植术,7例(14%)行经主动脉内膜切除术,4例(8%)行补片血管成形术,7例(15%)行联合手术。PTA/支架组的平均随访时间为15个月,OR组为42个月。研究终点包括围手术期发病率、死亡率、晚期生存率(Kaplan-Meier法)以及症状性和影像学复发情况。
除心脏病(P=0.025)和血清白蛋白<3.5g/dL(P=0.025)外,PTA/支架组和OR组患者的基线合并症相似。PTA/支架组血运重建的血管较少(1.5条对1.8条血管,P=0.001)。PTA/支架组的住院时间较短(5.6天对16.7天,P=0.001)。两组在院内主要并发症(4/31对2/49,P=0.23)或死亡率(1/31对1/49,P=0.74)方面无差异。两组在2年时的精算生存率相似(PTA/支架组为88%,OR组为74%,P=0.28)。两组在症状性复发率(7/31[23%]对11/49[22%],P=0.98)或影像学复发率(10/31[32%]对18/49[37%],P=0.40)方面无差异。与OR组相比,PTA/支架组在1年时的影像学主要通畅率(58%对90%,P=0.001)和主要辅助通畅率(65%对96%,P<0.001)较低。31例PTA/支架组患者中有5例(16%),49例OR组患者中有11例(22%)在任何时候至少需要对一条索引血管进行二次干预(P=0.49)。
对于CMI患者,开放治疗和血管内治疗后需要再次干预的症状性复发很常见(总体16/80[20%])。PTA/支架治疗与较低的主要通畅率、主要辅助通畅率以及更早进行再次干预的需求相关。接受PTA/支架治疗和OR治疗的患者在院内死亡率或主要并发症方面相似。这些发现表明,应根据患者个体的解剖结构和合并症情况,对CMI患者选择性地应用OR和PTA/支架治疗。